Individual Commitment: The Medicines Patent Pool (MPP) commits to facilitating access to the best available medicines for children. Specifically, the MPP will continue to work with patent holders to in-license paediatric drugs as prioritized by the WHO/PADO, and to sublicense to generic manufacturers to ensure that appropriate formulations are rapidly developed, registered and made available in as many developing countries as possible.

Individual commitment: MPP reports having increased the emphasis on recommended and priority paediatric drug formulations listed in WHO 2019 HIV guidelines and PADO 4 in the regular conversations with MPP licensees, while exploring with patent holders practical ways to further expand access to optimal formulations for paediatric populations. As part of this, MPP's dolutegravir (DTG) paediatric licence now allows for MPP licensees to manufacture any pharmaceutical composition that has been approved by the U.S. FDA and/or recommended by WHO for use in paediatric patients (HIV patients of less than 18 years old).

33. Inform all countries in the paediatric license group on the status of paediatric ARV patents.

33. MPP has started developing a summary overview document presenting the patent and licensing status, as well as information on optimal formulations and quality-approved sources of products recommended and prioritized in WHO HIV guidelines and PADO 4. MPP will be seeking input from GAP-f partners shortly as MPP assembles a pilot version to be transformed into a regularly updated webpage. MPP believes that summarizing this content into a single source and widely disseminating it will help countries, procurement agencies, HIV service delivery organizations and other stakeholders navigate access to affordable, quality-approved versions of recommended and priority paediatric ARVs more easily.